These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38892809)

  • 41. Advances in Brain Amyloid Imaging.
    Krishnadas N; Villemagne VL; Doré V; Rowe CC
    Semin Nucl Med; 2021 May; 51(3):241-252. PubMed ID: 33482999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular targeting and translational research for new therapeutic strategies on Alzheimer's disease].
    Takata K
    Yakugaku Zasshi; 2013; 133(12):1389-99. PubMed ID: 24292188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review.
    Jeremic D; Jiménez-Díaz L; Navarro-López JD
    Ageing Res Rev; 2021 Dec; 72():101496. PubMed ID: 34687956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.
    Boutajangout A; Wisniewski T
    Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multipronged diagnostic and therapeutic strategies for Alzheimer's disease.
    Ramesh M; Govindaraju T
    Chem Sci; 2022 Nov; 13(46):13657-13689. PubMed ID: 36544728
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 48. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
    Imbimbo BP; Lozupone M; Watling M; Panza F
    Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Open questions for Alzheimer's disease immunotherapy.
    Golde TE
    Alzheimers Res Ther; 2014; 6(1):3. PubMed ID: 24393284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AD "Statin": Alzheimer's Disorder is a "Fast" Disease Preventable by Therapeutic Intervention Initiated Even Late in Life and Reversible at the Early Stages.
    Volloch V; Olsen BR; Rits S
    Ann Integr Mol Med; 2020; 2(1):75-89. PubMed ID: 32201863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?
    Di Natale G; Sabatino G; Sciacca MFM; Tosto R; Milardi D; Pappalardo G
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Photoresponsive materials for intensified modulation of Alzheimer's amyloid-β protein aggregation: A review.
    Liu W; Dong X; Liu Y; Sun Y
    Acta Biomater; 2021 Mar; 123():93-109. PubMed ID: 33465508
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunosenescence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer's Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis.
    Bowirrat A
    J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting neuroinflammation in Alzheimer's disease.
    Bronzuoli MR; Iacomino A; Steardo L; Scuderi C
    J Inflamm Res; 2016; 9():199-208. PubMed ID: 27843334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review.
    Vicente-Zurdo D; Rosales-Conrado N; León-González ME
    Talanta; 2024 Mar; 269():125519. PubMed ID: 38086100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.